FinlandFinland

Genetic Cause for Dyslexia

16.09.2003

Helsinki - Dyslexia, a learning disability affecting up to 10 % of people, may have a genetic component. By analyzing individuals from 20 finnish families with several cases and comparing previously narrowed-down target areas in dyslexic and non-dyslexic members of each family, scientists around Juha Kere identified a gene called DYX1C1 that proved to be faulty in many cases (PNAS Online, August 25-29, 2003). The gene was either disrupted or carried a stop signal in the wrong place, producing a truncated protein. The native protein might help brain cells deal with metabolic stress. The scientists believe dyslexia to be a “genetically complex condition” with other faulty genes yet to be found.

FinlandFinland

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the...

FinlandFinland

07.03.2012

Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten...

FinlandFinland

02.03.2012

Lappeenranta – Finnish paper industry major UPM plans to invest in an industry-scale biorefinery producing biofuels from crude tall oil, a by-product of the wood pulp manufacturing process. UPM’s total investment will amount to...

FinlandFinland

18.12.2011

Helsinki/Göttingen – Finnish laboratory supplier Biohit Oyj has sold its liquid handling business for €68m to German process and labtech provider Sartorius AG. Osmo Suovaniemi, founder and Chairman of the Board at Biohit,...

FinlandFinland

17.12.2011

Porvoo/Chalfont St. Giles – GE Healthcare and Neste Jacobs have formed a strategic alliance to drive worldwide self-sufficiency in blood plasma fractionation. Finnish-based Neste Jacobs Oy, a global expert in plant engineering...

FinlandFinland

31.10.2011

Bresso/Turku – The wedding's off between Newron and Biotie. The bride has run away. Shares in Italy's Newron Pharmaceuticals plunged after its proposed merger with Biotie Therapies Corp was called off by the Finnish firm....

FinlandFinland

28.09.2011

Turku/ Bresso – It is both good and bad news for the Italian biotechnology sector: Finnish Biotie Therapies ASA has signed an agreement to acquire Newron Pharmaceuticals S.p.A. for €45 million. On the down side, Italy loses one...

FinlandFinland

04.04.2011

Hafnarfjodur – Actavis Group CEO Claudio Albrecht announced at the beginning of February that the company may go public within the next 2-3 years, although it isn’t clear whether the generics manufacturer would conduct an IPO,...

Displaying results 1 to 10 out of 96

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-finland/article/genetic-cause-for-dyslexia.html

Image Gallery

Stock list

All quotes

TOP

  • THROMBOGENICS (B)22.00 EUR16.5%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CLAVIS PHARMA (N)2.18 NOK6.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • DIAGENIC (N)0.79 NOK-38.3%
  • PAION (D)3.08 EUR-18.5%

TOP

  • WILEX (D)1.04 EUR79.3%
  • CO.DON (D)3.10 EUR74.2%
  • BIOTECH PHARMACON (N)18.20 NOK56.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • BIONOR PHARMA (N)2.08 NOK-48.6%
  • DIAGENIC (N)0.79 NOK-45.9%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP5998.1%
  • IXICO (UK)69.50 GBP768.8%
  • PLETHORA (UK)10.75 GBP563.6%

FLOP

  • CYTOS (CH)0.15 CHF-96.4%
  • EVOCUTIS (UK)0.25 GBP-91.4%
  • AGENNIX (D)0.04 EUR-82.6%

No liability assumed, Date: 14.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main

7th DVFA Life Science Conference

White Paper